New hope for Tough-to-Treat skin cancer: trial tests Triple-Drug attack
Disease control
Recruiting now
This early-stage study is testing the safety and best dose of adding a drug called nilotinib to standard treatments for advanced melanoma that has a specific genetic change (BRAF V600) and has stopped responding to current targeted therapies. The goal is to see if this three-drug…
Phase: PHASE1 • Sponsor: Rina Plattner • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC